CD47 Knock‐Out Using CRISPR‐Cas9 RNA Lipid Nanocarriers Results in Reduced Mesenchymal Glioblastoma Growth In Vivo

CD47 Knock‐Out Using CRISPR‐Cas9 RNA Lipid Nanocarriers Results in Reduced Mesenchymal Glioblastoma Growth In Vivo

Abstract Immune checkpoint (ICP) blockade has shown limited effectiveness in glioblastoma (GBM), particularly in the mesenchymal subtype, where interactions between immune cells and glioblastoma cancer stem cells (GSCs) drive immunosuppression and therapy resistance. Tailoring ICPs specific to GSCs...

Full description

Saved in:
Bibliographic Details
Main Authors: Nadia Rouatbi, Adam A. Walters, Alaa Zam, Yau Mun Lim, Alessia Marrocu, Revadee Liam‐Or, Joanne E. Anstee, James N. Arnold, Julie Tzu‐Wen Wang, Steven M. Pollard, Khuloud T. Al‐Jamal
Format: Article
Language:English
Published: Wiley 2025-03-01
Series:Advanced Science
Subjects:
CD47
glioblastoma
immune checkpoint
immunotherapy
nanoparticles
nucleic acid delivery
Online Access:https://doi.org/10.1002/advs.202407262
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/advs.202407262

Similar Items